News Releases



AACR CEO Margaret Foti Honored With Ovarcome Excellence Award167165/23/2016 7:48:22 PM Releases/AllItems.aspx899False2016-05-23T19:30:00Z<div class="ExternalClass8F728314C3A942238E7C84ABF62B9B12"><p>​PHILADELPHIA — Margaret Foti, PhD, MD (hc), chief executive officer (CEO) of the <a href="/Pages/Home.aspx">American Association for Cancer Research </a>(AACR), has received the Ovarcome Excellence 2016 Award in recognition of her accomplishments in the field of cancer research and her commitment to increasing public awareness about cancer and improving the lives of ovarian cancer survivors.<img alt="Foti and Sen150x200.jpg" src="/Newsroom/PublishingImages/Lists/News%20Releases/AllItems/Foti%20and%20Sen150x200.jpg" style="margin&#58;10px 5px;vertical-align&#58;auto;float&#58;right;" /></p><p>The Overcome Excellence Award is bestowed annually by Ovarcome Non-Profit Inc., a Houston-based foundation founded in 2012. The award recognizes an individual who has had a significant impact on research and treatment of ovarian cancer. Foti accepted the award on Saturday, May 21, at Ovarcome’s annual gala in Houston, where she delivered the keynote address. </p><p>“I am deeply honored to be recognized with the Ovarcome Excellence Award,” said Foti. “There has been great progress in cancer research and treatment; however, unfortunately, ovarian cancer remains difficult to treat, since it is often not detected until it has reached an advanced stage. My sister is an ovarian cancer survivor of 19 years, and her experience with the disease has inspired my strong desire to find cures for ovarian cancer as soon as possible.”</p><p>Ovarcome’s mission is to raise global awareness, to fund research in search of a cure, and to provide financial support to underprivileged women in the United States and in developing nations in their fight against ovarian cancer. Ovarcome awards grants for breakthrough ovarian cancer research to impact early detection, novel treatments, and patient survival.</p><p>“It is our absolute privilege and honor to bestow the Ovarcome Excellence Award 2016 to Dr. Margaret Foti,” said Runsi Sen, founder, president, and chief executive officer of Ovarcome. “Her personal connection and commitment to ovarian cancer and her extraordinary leadership in advancing the mission of global cancer research make us immensely proud to have the opportunity to recognize her.”</p><p>The AACR has numerous programs and initiatives to promote ovarian cancer research and awareness, including meetings and special conferences that bring together leading experts in the field. In September 2016, the AACR and the Rivkin Center for Ovarian Cancer will sponsor the 11th Biennial Ovarian Research Symposium in Seattle. The AACR is also the Scientific Partner of Stand Up to Cancer (SU2C), which funds cancer research through Dream Teams. The SU2C-Ovarian Cancer Research Fund Alliance-National Ovarian Cancer Coalition Dream Team brings together internationally renowned experts to create new programs in discovery, translation, and clinical application in the quest to cure ovarian cancer.</p><p>During Foti’s tenure as CEO of the AACR, her leadership has increased the organization’s membership, which has grown from about 3,000 to more than 36,000 laboratory, translational, and clinical researchers; population scientists; other health care professionals; and cancer advocates residing in 104 countries and territories around the world. In addition, the organization’s scientific meetings, peer-reviewed journals, and science policy work have furthered progress against all cancers through research, education, communication, and collaboration. The AACR has expanded its presence as a proponent of policies that support all aspects of cancer research and prevention, most recently providing guidance to Vice President Joe Biden as he begins to lead a new national effort against cancer.</p><p>Foti’s contributions have been widely recognized by numerous awards from organizations around the world. Her extensive list of formal recognitions includes honorary degrees in medicine and surgery from the University of Rome La Sapienza and the University of Catania in Sicily, and an honorary degree in medicine from the University CEU of San Pablo in Madrid. Most recently, she was honored by Massachusetts General Hospital Cancer Center as a 2015 honoree of “the one hundred.” She was also the recipient of the Children’s Champion Award from Children’s Hospital of Philadelphia in 2015, the 2014 Ellen V. Sigal Advocacy Leadership Award from Friends of Cancer Research, the 2014 Morton M. Kligerman Visiting Professorship Award from the University of Pennsylvania, the 2013 Stanley P. Reimann Honor Award from Fox Chase Cancer Center, and the 2013 Distinguished Partner in Hope Award from the Abramson Cancer Center of the University of Pennsylvania.</p></div>
American Association for Cancer Research Returns as Charity Title Partner of <br>Rock ‘n’ Roll Philadelphia Half Marathon161915/23/2016 7:06:33 PM Releases/AllItems.aspx898False2016-05-23T19:00:00ZAnnual fall race returns to Philadelphia the weekend of September 16-18, 2016<div class="ExternalClass557D5528524A4D46A6E6741E19719B0C"><p>​PHILADELPHIA&#160;— The Rock 'n' Roll Marathon Series today announced the renewed charity title partnership of the American Association for Cancer Research (AACR), the largest scientific organization in the world supporting cancer research, at the 2016 Rock 'n' Roll Philadelphia Half Marathon.</p><p><img src="/PublishingImages/RnR_Philadelphia_2016_320.jpg" alt="" style="margin&#58;5px 10px;vertical-align&#58;auto;float&#58;right;" />&quot;With more than 14.5 million cancer survivors and 1.6 million who will be diagnosed with cancer in the United States this year, the American Association for Cancer Research is dedicated to finding a cure and preventing the more than 200 diseases we call cancer,&quot; said Mitch Stoller, Executive Director, AACR Foundation. &quot;Philanthropy dedicated to cancer research is paramount to accomplish this. Headquartered in Philadelphia, the AACR is thrilled to return as the charity title partner for the Rock 'n' Roll Philadelphia Half Marathon, and invites participants to join the AACR's Runners for Research team in our quest to find cures together.&quot;</p><p>The AACR is the first and largest cancer research organization in the world, bringing together the greatest minds in cancer research in the quest to cure and prevent cancer through research, education, communication, and collaboration. The AACR is known throughout the cancer research community as a catalyst to propel the advancement of cancer research and improve patient care by convening and collaborating with the public, physicians, researchers, academia, advocacy organizations, industry, government, and scientific societies. Recently, the AACR and its 36,000 members have been called upon to help guide the National Cancer Moonshot Initiative led by Vice President Joe Biden, whose mission is to &quot;end cancer as we know it.&quot; The AACR is also the Scientific Partner to Stand Up To Cancer, providing scientific oversight of team science and individual grants that have potential for near-term patient benefit. These are two of countless initiatives where the work of the AACR helps to accelerate progress against cancer.</p><p>&quot;There is no greater camaraderie than running for a cause such as cancer research,&quot; said Dave Hussa, Vice President of Charity Partnerships for Rock 'n' Roll Marathon Series. It is our goal to help spread the American Association for Cancer Research's mission of finding a cure and preventing cancer, and we look forward to welcoming AACR Runners for Research for the second year in a row to this annual fall race.&quot;</p><p>The American Association for Cancer Research Rock 'n' Roll Philadelphia Half Marathon will take place on Sunday, September 18, and will start and finish in downtown Philadelphia. Runners will travel past Philadelphia's historical landmarks, scenic neighborhoods, and beautiful parks. Live bands, enthusiastic cheerleaders, and spectators will entertain participants along the scenic course. Upon finishing, participants are invited to relax and celebrate with family and friends at the post-race finish line festival.</p><p>The Rock 'n' Roll 5K returns this year on Saturday, September 17, and will start and finish in downtown Philadelphia. Participants who run both the 5K and the half marathon will earn the coveted Remix Challenge Medal in addition to each race's finisher medal.</p><p>Race weekend kicks off with a free Health &amp; Fitness Expo, where exhibitors will offer free samples, showcase the latest in running gear, sports apparel, health and nutritional information, and much more. The Expo takes place at the Pennsylvania Convention Center on Friday, September 16, from 12 p.m. to 7 p.m. and Saturday, September 17, from 9 a.m. to 5 p.m. The Expo is free and open to the public.</p><p>Over the 19-year history of the Rock 'n' Roll Marathon Series, charity participants have raised more than $320 million for a variety of worthy causes and nonprofit organizations. For more information on the Rock 'n' Roll Marathon Series, visit <a href="http&#58;//" target="_blank"></a> or follow <a href="http&#58;//" target="_blank">@RunRocknRoll</a> and <a href="https&#58;//" target="_blank">@AACR</a> on Twitter.</p><p>Participants can run and support a good cause by joining the AACR Runners for Research team. For more information or to register visit <a href="/RunPhilly" target="_blank"></a>.</p></div>
Investigational CDK4/6 Inhibitor Abemaciclib is Active Against a Range of Cancer Types73255/23/2016 2:02:53 PM Releases/AllItems.aspx897False2016-05-23T04:05:00Z<div class="ExternalClass68BBC91848A344688AC9E041FAF19076"><p>PHILADELPHIA — The investigational anticancer therapeutic abemaciclib, which targets CDK4 and CDK6, showed durable clinical activity when given as continuous single-agent therapy to patients with a variety of cancer types, including breast cancer, non–small cell lung cancer (NSCLC), glioblastoma, and melanoma, according to <a href="http&#58;//" target="_blank">results from a phase I clinical trial</a> published in <em>Cancer Discovery</em>, a journal of the American Association for Cancer Research.<img alt="Amita Patnaik" src="/PublishingImages/Patnaik_Amita_150x200.jpg" style="margin&#58;10px;vertical-align&#58;auto;float&#58;right;" /></p><p>The results of the trial supported the U.S. Food and Drug Administration (FDA) decision to grant breakthrough therapy designation to abemaciclib (previously known as LY2835219) for patients with refractory hormone receptor–positive advanced or metastatic breast cancer, according to one of the senior authors of the study, <a href="http&#58;//">Amita Patnaik, MD</a>, associate director of clinical research at <a href="http&#58;//">South Texas Accelerated Research Therapeutics </a>in San Antonio, Texas.</p><p>In February 2015, the FDA <a href="http&#58;//">approved </a>the CDK4/6 inhibitor palbociclib (Ibrance) for use in combination with the aromatase inhibitor letrozole for treating postmenopausal women with estrogen receptor–positive, HER2-negative advanced breast cancer.</p><p>“Abemaciclib, an oral CDK4/6 inhibitor, is a very different molecule from palbociclib, with distinct attributes that contribute to its discrete therapeutic effects, in particular, its single-agent activity,” said the other senior author of the study, <a href="http&#58;//">Geoffrey I. Shapiro, MD, PhD</a>, director of the <a href="http&#58;//">Early Drug Development Center </a>at the Dana-Farber Cancer Institute in Boston. “For example, abemaciclib has greater selectivity for CDK4 compared with palbociclib, which may explain why it does not affect white blood cell counts as severely, allowing it to be taken on a continuous schedule without treatment holidays. Abemaciclib also penetrates the central nervous system, whereas palbociclib does not, raising the possibility that it could be used to treat primary or metastatic brain tumors.”<img alt="Geoffrey Shapiro" src="/PublishingImages/Shapiro_Geoffrey_150x200.jpg" style="margin&#58;10px;vertical-align&#58;auto;float&#58;right;" /></p><p>Patnaik, Shapiro, and colleagues enrolled 225 patients with a variety of types of advanced cancer in the phase I clinical trial designed to evaluate the safety and preliminary efficacy of abemaciclib. In the dose escalation phase, the researchers determined that the maximum tolerated dose was 200 milligrams (mg) every 12 hours; the dose-limiting toxicity was grade 3 fatigue.</p><p>In the expansion phase, single-agent abemaciclib was administered to 47 patients with breast cancer, 68 with NSCLC, 17 with glioblastoma, 26 with melanoma, and 15 with colorectal cancer. Among these patients, the most common treatment-related adverse events were fatigue, diarrhea, nausea, vomiting, anorexia, weight loss, kidney dysfunction, and decreased red and white blood cell counts.</p><p>Radiographic responses were observed for some patients with breast cancer, NSCLC, and melanoma. Among the 36 patients with hormone receptor–positive breast cancer, 11 had a partial response, with four of the 11 responders having continued prior endocrine therapy, and an additional 18 patients had stable disease. Among the 68 patients with NSCLC, two had a partial response and 31 had stable disease; one patient who had a partial response and 12 who had stable disease were known to have KRAS-mutant NSCLC. Among the 26 patients with melanoma, one had a partial response and six had stable disease. Three of the 17 patients with glioblastoma had stable disease, with two of them continuing to receive treatment without disease progression for 19 and 23 cycles, respectively.</p><p>“These data show that abemaciclib is an oral drug that can be taken on a continuous schedule and achieve durable clinical activity against multiple tumors including breast and lung cancers,” said Shapiro. </p><p>“However, because this study included 225 patients with different types of cancer, confirmatory clinical trials in specific patient populations are necessary to precisely define the role of abemaciclib in cancer care,” added Patnaik. “Multiple clinical trials have already been initiated to evaluate abemaciclib as a treatment for certain groups of patients with breast cancer and NSCLC, as well as children with primary brain tumors and adults with brain metastases.”</p><p>The study was funded by Eli Lilly and Company. Patnaik has received research funding from Lilly. Shapiro served on an advisory board for Lilly during the conduct of the study; reports receiving personal fees from Lilly, GI Therapeutics, Vertex Pharmaceuticals, and grants from Lilly for work other than reported here; and is an investigator on several trials using other CDK4/6 inhibitors, including palbociclib and ribociclib.<br></p></div>
A Liquid Biopsy–based Test to Detect BRAF V600 Mutations in Advanced Cancers is Comparable to Standard Invasive Tests161455/20/2016 2:18:30 PM Releases/AllItems.aspx896False2016-05-20T04:05:00ZTest has 90-minute turnaround time and can predict therapy response over the course of treatment<div class="ExternalClass99A430AF368D453EBF258FB90980302E"><p>PHILADELPHIA — Testing for BRAF V600 mutations in cell-free DNA from plasma using the PCR-based IdyllaTM BRAF Mutation Test was feasible and concordant with standard tests of archival tumor biopsy samples and had a short turnaround time of 90 minutes, according to a <a href="http&#58;//">study </a>published in <em>Molecular Cancer Therapeutics</em>, a journal of the American Association for Cancer Research.<img alt="Filip Janku" src="/PublishingImages/Janku_Filip_150x200.jpg" style="margin&#58;10px;vertical-align&#58;auto;float&#58;right;" /></p><p>“Cell-free DNA is released to the circulation from cancer cells undergoing apoptosis or necroptosis in the primary or metastatic cancer lesions and can be detected in the blood,” said <a href="http&#58;//" target="_blank">Filip Janku, MD, PhD</a>, assistant professor of Investigational Cancer Therapeutics (Phase I Clinical Trials Program) at <a href="https&#58;//">The University of Texas MD Anderson Cancer Center </a>in Houston.</p><p>“Unlike performing tissue biopsies, obtaining blood samples to isolate cell-free DNA is a minimally invasive approach with less risk to the patients at a lower cost,” Janku added. “The samples can be collected at multiple time points and provide valuable information about the genetic changes that occur during the course of the disease, as this is not a static process.</p><p>“We developed Idylla<sup>TM</sup> BRAF Mutation Test, a fully integrated quantitative allele-specific real-time PCR-based test that uses a single disposable cartridge. We demonstrated that testing for BRAF V600 mutations in plasma cell-free DNA using this test is feasible, has comparable sensitivity and specificity to other PCR or next-generation sequencing methods, and has an unprecedented short turnaround time,” Janku said.</p><p>Janku and his colleagues used plasma samples collected from 160 patients with a range of advanced cancers with known BRAF V600 mutation status determined using paraffin-embedded tumor tissue samples. The most common tumor types were colorectal cancer and melanoma.</p><p>The researchers analyzed the plasma samples for BRAF V600 mutations using the Idylla system and found that the test had 88 percent concordance with the results from the standard tests that used paraffin-embedded tissues, in samples collected at baseline. The concordance was 90 percent when results from samples collected at any time point during the course of the treatment were compared.</p><p>The new test had 73 percent sensitivity and 98 percent specificity, with a positive-predictive value of 96 percent (meaning that it correctly predicted a positive result 96 times out of 100) and a negative-predictive value of 85 percent (meaning that it correctly predicted a negative result 85 times out of 100).</p><p>The researchers also found that the amount of BRAF V600 mutant cell-free DNA, as detected by the Idylla system, was predictive of overall survival of the patients&#58; In patients with a BRAF-mutant cell-free DNA percentage of 2 or less, overall survival was 10.7 months, compared with 4.4 months in those who had more than 2 percent of BRAF V600 mutations in their samples.</p><p>The amount of cell-free DNA present in the plasma by itself was not predictive of survival outcomes.</p><p>In patients whose baseline samples were negative for BRAF V600 mutations, the time to treatment failure (TTF) was 13.1 months after treatment with BRAF and/or MEK inhibitors, as opposed to those whose baseline samples were positive for the mutation, in whom the TTF was three months. Patients whose baseline samples were negative for BRAF V600 mutations were 69 percent less likely to see their therapy fail, compared with those whose baseline samples were positive for the mutation.</p><p>“Our results suggest that high amounts of BRAF-mutant cell-free DNA before therapy is a negative prognostic biomarker for survival and outcomes of targeted therapy. It was somewhat counterintuitive since one would assume that more BRAF-mutant copies in the circulation would rather predict better outcomes with BRAF-targeted therapies,” Janku said. “We also showed that a decrease in the amount of BRAF-mutant cell-free DNA in sequentially collected plasma samples correlates with better treatment outcomes.”</p><p>As limitations to the study, Janku said that the team investigated only BRAF V600 mutations, which are clinically relevant to a limited number of patients with certain tumor types. Second, the survival and treatment outcomes analyses were retrospective and need to be validated in future prospective studies, he added. Also, the clinical utility of cell-free DNA mutation testing remains to be proven in prospective clinical trials in which therapeutic interventions are tailored on the basis of patients’ respective cell-free DNA mutation statuses, Janku cautioned.</p><p>The study was supported by Biocartis, the Elsa U. Pardee Foundation, and the Sidney Kimmel Foundation for Cancer Research. Janku has research support from Novartis, Biocartis, Trovagene and Transgenomic.<br></p></div>
University of Catania Presents Margaret Foti Scholar-in-Training Award to Dr. Saverio Candido 166815/18/2016 3:08:53 PM Releases/AllItems.aspx895False2016-05-17T20:45:00Z<div class="ExternalClass19EB0AD9FE8240E08FFA5775CDF6285F"><p>​PHILADELPHIA — The American Association for Cancer Research (AACR) congratulates Saverio Candido, PhD, on receiving the Fourth Margaret Foti Scholar-in-Training Award from the University of Catania in Italy. Candido is being recognized for his research on biomarkers of bladder cancer development and progression.</p><p>The award, established in 2010, is named in honor of Margaret Foti, PhD, MD (hc), chief executive officer of the AACR, and recognizes a young investigator who has completed a doctoral program in the oncological sciences at the University of Catania and who has conducted meritorious research in the field of translational oncology.</p><p>Candido's research has shown that the proteins NGAL and MMP9 may be useful as biomarkers for the development of diagnostic and prognostic tests for bladder cancer patients, potentially reducing the need for invasive and expensive surgical procedures and also for helping with the ongoing management of their disease after diagnosis.</p><p>&quot;I am very honored to present the Margaret Foti Scholar-in-Training Award to Dr. Candido and am delighted that the scientific achievements of a promising young investigator are being recognized through this award,&quot; Foti said. &quot;Dr. Candido's research explores new biomarkers for bladder cancer, a disease that is the fourth most common cancer among men in developed countries. It is wonderful that he is receiving this travel grant from the Italian League Against Cancer of Catania to attend the 2017 AACR Annual Meeting in Washington, D.C., and we will look forward to hearing his presentation at our meeting.&quot; </p><p>Foti added, &quot;My sincere appreciation goes to President Carlo Romano of the Catania Section of the Italian League Against Cancer for his input into the organization of the symposium and, in particular, for funding the Foti Award. I would also like to thank and recognize Professor Massimo Libra, Dr. Candido's tutor, and Professor Ferdinando Nicoletti for his expert guidance of this stellar program that trains the next generation of cancer researchers.&quot;</p><p>Candido received the award at the Symposium on Patient-Centered Care in Oncology&#58; Risk Factors, Nutrition and Novel Therapies at the University of Catania. The Italian League Against Cancer of Catania will provide Candido with a travel grant to attend the <a href="/Meetings/Pages/MeetingDetail.aspx?EventItemID=105">AACR Annual Meeting 2017</a>, to be held April 1-5, in Washington, D.C. </p><p>&#160;</p></div>
New Biomarker Identifies Colorectal Cancer Patients Likely to Benefit Most from Cetuximab Treatment166725/17/2016 4:57:03 PM Releases/AllItems.aspx894False2016-05-13T04:05:00Z<div class="ExternalClass902A6F03ADBD4BEAA46E648CB2599EA8"><p>​PHILADELPHIA — Among patients with metastatic colorectal cancer harboring normal forms of the KRAS gene, only those who had two copies of a specific version of the FCGR2A gene (FCGR2A H/H) had a statistically significant increase in median overall survival when cetuximab (Erbitux) treatment was added to best supportive care, according to a <a href="http&#58;//" target="_blank">retrospective analysis of data </a>from a <a target="_blank" href="https&#58;//;rank=1">phase III clinical trial</a> published in <em>Clinical Cancer Research</em>, a journal of the American Association for Cancer Research.<img src="/PublishingImages/Liu_Geoffrey_150x200.jpg" alt="Geoffrey Liu" style="margin&#58;10px;float&#58;right;" /></p><p>Median overall survival among FCGR2A H/H patients with metastatic colorectal cancer harboring normal forms of the KRAS gene (KRAS-wildtype) was 5.5 months longer for those who received cetuximab in addition to best supportive care (10.35 months versus 4.83 months). This was a statistically significant increase in median overall survival. Among patients with KRAS-wildtype disease who had one copy of the specific variant (FCGR2A H/R) or no copies (FCGR2A R/R), the increases in median overall survival were not statistically significant, at 3.9 and 1.7 months, respectively.</p><p>“After research showed that cetuximab treatment did not benefit patients with metastatic colorectal cancer harboring a mutated KRAS gene, the U.S. Food and Drug Administration <a target="_blank" href="http&#58;//">restricted use </a>of the anticancer agent to patients whose colorectal cancer tumors had no KRAS gene mutations,” said <a target="_blank" href="http&#58;//">Geoffrey Liu, MD</a>, the Alan B. Brown Chair in Molecular Genomics at the <a href="http&#58;//">Princess Margaret Cancer Centre</a> in Toronto. “Even so, almost half of the patients with metastatic colorectal cancer receiving cetuximab do not derive much benefit from this treatment. We wanted to find new biomarkers that could improve the way we personalize cetuximab treatment.</p><p>“We found that patients with the FCGR2A H/H genotype benefited most from cetuximab, those with the FCGR2A H/R genotype had marginal benefit, and those with the FCGR2A R/R genotype had no real benefit,” continued Liu. “If our findings are validated in prospective trials, they suggest that the 25 percent of people who carry the FCGR2A R/R genotype should be treated with therapies other than cetuximab so that they do not experience the potential harmful toxicities of an anticancer agent that will be very unlikely to benefit them.”</p><p>Liu and his colleagues in the <a target="_blank" href="https&#58;//">Canadian Cancer Trials Group </a>and the <a target="_blank" href="http&#58;//">Australasian Gastro-Intestinal Trials Group </a>analyzed archived tumor and normal tissue samples from patients enrolled in the phase III NCIC-CTG CO.17 clinical trial. Between December 2003 and August 2005, 572 patients with metastatic colorectal cancer were enrolled in the trial evaluating the addition of cetuximab to best supportive care for patients with metastatic colorectal cancer.</p><p>Previously published results from the trial reported that adding cetuximab to best supportive care increased median overall survival, and that the benefits of cetuximab were restricted to patients with KRAS-wildtype disease.</p><p>In this study, the researchers were able to identify the FCGR2A genotype of 286 patients, 148 of whom had KRAS-wildtype tumors.</p><p>According to Liu, the major limitations of the study are the retrospective nature of the analyses and the need for confirmation of the results in multiple studies before they can be used to guide clinical decision making. He added that a study to validate the findings, called CO.20, which is spearheaded by the Canadian Cancer Trials Group and the Australasian Gastro-Intestinal Trials Group, is already underway.</p><p>The study was supported by the Ontario Institute for Cancer Research, the Canadian Cancer Society, Transgenomic Inc., the Canadian Institutes of Health Research, and the Peter MacCallum Cancer Foundation. Liu declares no conflicts of interest.<br></p></div>
AACR/AACI/ASCO to Honor U.S. Representatives Castor, Fleischmann as part of Capitol Hill Day to Advocate for Cancer Research Funding during National Cancer Research Month166035/11/2016 5:19:05 PM Releases/AllItems.aspx893False2016-05-11T17:20:00Z<div class="ExternalClass57C841D53B4644FE862EDF5487481BB2"><p>​The American Association for Cancer Research (AACR), the Association of American Cancer Institutes (AACI), and the American Society of Clinical Oncology (ASCO) will honor U.S. Representatives Kathy Castor (D-Fla.) and Chuck Fleischmann (R-Tenn.) for their outstanding leadership on behalf of cancer research at a reception on May 11. On May 12, cancer researchers, physicians, survivors, patient advocates, and cancer center directors associated with the AACI, AACR, and ASCO will call on Congress to provide robust, sustained, and predictable funding increases for the National Institutes of Health (NIH) and the National Cancer Institute&#160; (NCI) in fiscal year 2017 and beyond.</p><p>Reps. Castor and Fleischmann have been outspoken supporters of the NIH and the NCI. Since first taking office in 2007, Castor has been an outstanding champion for cancer research and has fought tirelessly for increases to the NIH budget and for research funding through other federal agencies. A strong proponent of cancer prevention, for the past two years Castor has spearheaded a far-reaching campaign to promote awareness of the HPV vaccine and how it can prevent certain kinds of cancers. She also joined her colleague Rep. Renee Ellmers (R-N.C.) in working to advance the Accelerating the End of Breast Cancer Act, H.R.1197, to the House floor for a vote earlier this year.</p><p>Rep. Fleischmann has represented the third district of Tennessee since 2010. He currently serves on the House Appropriations Subcommittee on Labor, Health and Human Services, where he is a devoted advocate for the cancer community. Fleischmann encourages cancer patients to share their stories and has further opened the dialogue in Congress about the need for more research to bring more cures. He has repeatedly called for a national commitment to defeat cancer, and readily shares his personal experiences to bring hope to others.</p><p>In 2015, Congress passed a bipartisan spending bill that provided the NIH with a $2 billion increase in federal funding for fiscal year 2016 — the largest boost in annual appropriations for the NIH in more than a decade. Cancer researchers, physician-scientists, the nation's cancer centers, and cancer patients depend on robust, predictable, and sustained funding increases for the NIH and NCI in order to increase the pace of progress against cancer.</p><p>For the past 10 years, each May, which is National Cancer Research Month, the AACI, AACR, and ASCO have converged on Capitol Hill to share how cancer research is saving lives and transforming patient care. These groups are the three largest organizations in the field, representing more than 60,000 cancer researchers and community oncologists, and 95 cancer centers across the U.S. This year, advocates will thank members of Congress for their renewed commitment to the NIH and NCI in fiscal year 2016, and they will urge Congress to continue the momentum by providing a $2.4 billion increase for the NIH in fiscal year 2017.</p></div>
American Association for Cancer Research Recognizes National Cancer Research Month in Partnership with Nation’s Legislators, Cancer Advocacy Organizations, and Patient Advocates165785/10/2016 6:27:20 PM Releases/AllItems.aspx891False2016-05-10T17:25:00Z<div class="ExternalClass368E1AF5622744F483EC824EA2E2DCE4"><p>​PHILADELPHIA — The American Association for Cancer Research (AACR) proudly recognizes May 2016 as National Cancer Research Month and wishes to express its appreciation to U.S. Representatives Kevin Yoder (R-Kan.) and Emanuel Cleaver (D-Mo.), U.S. Senators Dianne Feinstein (D-Calif.) and Johnny Isakson (R-Ga.), dozens of cancer advocacy organizations, and thousands of cancer physicians, researchers, survivors, and patient advocates for their support in promoting how cancer research saves lives, and advocating for robust, sustained, and predictable federal funding increases for cancer research and biomedical science.</p><p>On Monday, May 9, Senators Feinstein and Isakson introduced resolution <a href="https&#58;//" target="_blank">S. Res. 459</a> &quot;recognizing the importance of cancer research and the vital contributions of scientists, clinicians, cancer survivors, and other patient advocates across the United States, who are dedicated to finding a cure for cancer, and designating May 2016 as 'National Cancer Research Month.'&quot; The resolution is a companion to <a href="https&#58;//" target="_blank">H. Res. 717</a>, introduced in the U.S. House of Representatives on April 29 by Reps. Yoder and Cleaver. Supporters are encouraged to <a href="http&#58;//" target="_blank">write their members of Congress</a> to urge them to prioritize funding for the NIH and to cosponsor H. Res. 717 and S. Res. 459 as a show of support for cancer research.</p><p>Also this week, the AACR will join the Association of American Cancer Institutes (AACI) and the American Society of Clinical Oncology (ASCO) in honoring Representatives Kathy Castor (D-Fla.) and Chuck Fleischmann (R-Tenn.) for their outstanding leadership on behalf of cancer research at a reception on Wednesday, May 11. On Thursday, May 12, cancer researchers, physicians, survivors, and patient advocates associated with AACR, AACI, and ASCO will advocate for increased funding for the National Institutes of Health and the National Cancer Institute during an annual Hill Day dedicated to underscoring how cancer research saves lives and transforms patient care.</p><p>Throughout the month of May, the AACR is spearheading a social media campaign called &quot;<a href="https&#58;//" target="_blank">Real Hope Is</a>,&quot; an opportunity to share what gives patients, survivors, caregivers, clinicians, and researchers real hope on their cancer journey. Submissions will be featured on the AACR's&#160;<a href="https&#58;//;ref=eyJzaWQiOiIwLjU0ODkyODEyNzA5OTEyNDkiLCJxcyI6IkpUVkNKVEl5Ym1GMGFXOXVZV3dsTWpCallXNWpaWElsTWpCeVpYTmxZWEpqYUNVeU1HMXZiblJvSlRJeUpUVkUiLCJndiI6ImJlZTA5ZjkzZmE3MzJjZmE1OWExY2I2ZDlmNDUwZDM4OTI0MjRlNDkifQ" target="_blank">National Cancer Research Month</a> Facebook page, and we encourage the sharing of stories on <a href="https&#58;//" target="_blank">Twitter</a> using the&#160;<a href="https&#58;//;q=%23RealHopeIs" target="_blank">#RealHopeIs</a> and <a href="https&#58;//" target="_blank">#NCRM16</a> hashtags.</p><p>The AACR has also launched a new advertising campaign on television, radio, and the Web featuring <a href="https&#58;//" target="_blank">Cancer Thrivers</a>. The concept behind the campaign celebrates cancer patients and survivors, recognizing that they are not merely surviving or living with cancer, but thriving thanks to cancer research. Cancer Thrivers will be joined in the campaign by Cure Drivers—cancer researchers whose work is enabling these cancer patients to thrive.</p><p>Follow National Cancer Research Month throughout May to keep apprised of the AACR's and the cancer research community's latest efforts to raise awareness of the importance of cancer research and advocate for increased funding.</p></div>
American Association for Cancer Research Recognized Research Grantees at the Annual Meeting 2016165845/10/2016 6:50:02 PM Releases/AllItems.aspx892False2016-05-10T04:05:00Z<div class="ExternalClass72264EF6A5CB449896BD6C0014624F3F"><p>​PHILADELPHIA — The American Association for Cancer Research (AACR) honored its new grant recipients at the Grants Reception and Dinner at the AACR Annual Meeting 2016, which was held in New Orleans April 16-20. </p><p>The AACR has been funding scientific research since 1993. Since the beginning of the grants program, AACR has awarded more than $300 million in funding to over 500 researchers. The AACR is proud to welcome these new grantees to a long and distinguished list of dedicated scientists who have been selected as AACR grant recipients.&#160; </p><p>Fellowships&#58; <br>2015 AACR-Amgen, Inc. Fellowships in Clinical/Translational Cancer Research<br>•&#160;Marisa M. Juntilla, MD, PhD, Stanford University, Stanford, California<br>“Translational Regulation by a Leukemia-specific Mutation in Nucleophosmin 1”<br>•&#160;Danny N. Khalil, MD, PhD, Memorial Sloan Kettering Cancer Center, New York<br>“Potentiating PD-1 Blockade in Resistant Cancers by Enforced APC Activation”</p><p>2016 AACR-Amgen, Inc. Fellowships in Clinical/Translational Cancer Research<br>•&#160;Willy Hugo, PhD, University of California, Los Angeles<br>“Innate Resistance to Immune Checkpoint Inhibition for Melanoma Therapy”</p><p>•&#160;Aparna Lakshmanan, PhD, The Ohio State University, Columbus, Ohio<br>“BRAF-mediated Immunomodulation in Disseminated B-cell Malignancy”</p><p>2015 AACR-Bristol-Myers Squibb Oncology Fellowship in Clinical Cancer Research<br>•&#160;Marco Ruella, MD, University of Pennsylvania, Philadelphia<br>“Dual Chimeric Antigen Receptor T cells for CD19-negative Leukemia Relapses”</p><p>2016 AACR-Bristol-Myers Squibb Oncology Fellowship in Clinical Cancer Research<br>•&#160;Yiting Lim, PhD, Fred Hutchinson Cancer Research Center, Seattle<br>“Dissecting Oncogenic Translation in Prostate Cancer Pathogenesis”</p><p>2016 AACR-Bayer Hepatocellular Carcinoma Research Fellowship<br>•&#160;Juyoun Kim, PhD, University of California, San Diego<br>“Role of TNF Signaling in De Novo Lipid Synthesis Upon Hypernutrition”</p><p>2016 AACR-Bayer Prostate Cancer Research Fellowship<br>•&#160;Sethuramasundaram Pitchiaya, PhD, University of Michigan, Ann Arbor<br>“Androgen Receptor Regulation by lncRNA PRCAT47 in Prostate Cancer”</p><p>2015 AACR Basic Cancer Research Fellowship<br>•&#160;Jason J. Northey, PhD, University of California, San Francisco<br>“Tissue Tension Promotes Stemness and Breast Cancer Aggression”</p><p>2016 AACR Basic Cancer Research Fellowships<br>•&#160;Elizabeth J. Adams, PhD, Memorial Sloan Kettering Cancer Center, New York<br>“Characterizing FOXA1 Mutations Using a Novel Prostate Organoid System”<br>•&#160;Shruti Bhatt, PhD, Dana-Farber Cancer Institute, Boston<br>“Mitochondrial Perturbations as a Novel Approach to Personalized Therapy”<br>•&#160;Karuna Ganesh, MD, PhD, Memorial Sloan Kettering Cancer Center, New York<br>“Investigating and Targeting L1CAM in Metastatic Cancer Stem Cells”<br>•&#160;Andrew W. Holle, PhD, Max Planck Institute for Intelligent Systems, Stuttgart, Germany<br>&#160;“Cancer Cell Cytoskeletal Dynamics during Confined Invasion”<br>•&#160;Wei Jin, PhD, Fred Hutchinson Cancer Research Center, Seattle<br>“Targeting Immunosuppressive Tumor Microenvironment Resulting from Therapy”<br>•&#160;Emil Schüler, PhD, Stanford University, Stanford, California<br>“Improved Therapeutic Index in the GI Tract with Ultra-fast Irradiation”<br>•&#160;Jie Su, PhD, Memorial Sloan Kettering Cancer Center, New York<br>“Dissecting TGFβ-induced Lethal EMT in KRAS-driven Pancreatic Cancer”<br>•&#160;April M. Weissmiller, PhD, Vanderbilt University, Nashville, Tennessee<br>“Probing a Novel Mechanism of MYC Recruitment to Chromatin”</p><p>2016 AACR Anna D. Barker Fellowship in Basic Cancer Research<br>•&#160;Neville Gilhooly, PhD, University of California, Davis<br>&#160;“How do Replication-Transcription Collisions Cause Genome Instability?”</p><p>2016 AACR-John and Elizabeth Leonard Family Foundation Basic Cancer Research Fellowship<br>•&#160;Fides D. Lay, PhD, University of California, Los Angeles<br>&#160;“The Role of Ldb1-mediated Enhancer-Promoter Communication in T-ALL”</p><p>2016 AACR Judah Folkman Fellowship for Angiogenesis Research<br>•&#160;Amelia A. Rand, PhD, University of California, Davis Comprehensive Cancer Center<br>&#160;“Regulation of Cancer Angiogenesis from the Metabolism of Epoxy Omega-6 Fats”</p><p>2016 AACR-Incyte Corporation Fellowship in Clinical Lymphoma Research<br>•&#160;Santosha A. Vardhana, MD, PhD, Memorial Sloan Kettering Cancer Center, New York<br>&#160;“Response and Resistance to Checkpoint Blockade in Hodgkin Lymphoma”</p><p>2016 AACR-Ocular Melanoma Foundation Fellowship<br>•&#160;Jessica Teh, PhD, Thomas Jefferson University, Philadelphia<br>&#160;“Utility of CDK4/6 Inhibitors in Uveal Melanoma”</p><p>2015 AACR Millennium Fellowships in Lymphoma Research<br>•&#160;Maite Alvarez, PhD, Stanford University, Stanford, California<br>&#160;“Improving Cancer Therapy for Lymphoma by Preventing NK-cell Exhaustion”<br>•&#160;Shenqiu Wang, PhD, Memorial Sloan Kettering Cancer Center, New York<br>“Genetic Causes of B-cell Receptor Activation in Follicular Lymphoma”</p><p>2015 AACR-Millennium Fellowship in Multiple Myeloma Research<br>•&#160;Bruno Paiva, PhD, University of Navarra, Pamplona, Spain <br>&#160;“Defining MRD and Stem Myeloma Clones to Understand Ultra-chemoresistance”</p><p>2016 AACR-Takeda Oncology Fellowships in Lymphoma Research<br>•&#160;Matthew Frank, MD, PhD, Stanford University, Stanford, California<br>&#160;“A Novel Bispecific Antibody for the Treatment of B-cell Lymphoma”<br>•&#160;Hsia-Yuan Ying, PhD, Weill Cornell Medical College, New York<br>&#160;“Mutational Cooperativity of CREBBP and KMT2D in B-cell Lymphoma”</p><p>2016 AACR-Takeda Oncology Fellowships in Multiple Myeloma Research<br>•&#160;Neelam Bhardwaj, PhD, University of Utah Huntsman Cancer Institute, Salt Lake City<br>&#160;“Generation of a Monoclonal Antibody Against VISTA for the Immunomodulatory &#160;Therapy of Multiple Myeloma”<br>•&#160;Barbara Castella, PhD, University of Torino, Torino, Italy<br>&#160;“Targeting Immune Inhibitory Pathways in the Bone Marrow of Myeloma &#160;Patients”</p><p>2016 Debbie’s Dream Foundation-AACR Gastric Cancer Research Fellowship<br>•&#160;Holly A. Martinson, PhD, University of Alaska Anchorage<br>&#160;“Discovering Biomarkers for Early Detection and Treatment of Gastric Cancer”</p><p>2016 Never Too Young Coalition-AACR Fellowship in Young-Onset Colorectal Cancer Research, supported by the Colon Cancer Alliance<br>•&#160;Tatianna C. Larman, MD, Johns Hopkins University, Baltimore<br>&#160;“Exploiting a Common Metabolic Susceptibility in Early-onset Sporadic CRC”</p><p>2016 Never Too Young Coalition-AACR Fellowship in Young-Onset Colorectal Cancer Research, supported by Michael's Mission and the Colon Cancer Alliance<br>•&#160;Sarah B. Stringfield, MD, University of California, San Diego<br>&#160;“Young-onset Colorectal Cancer - A Virally Mediated Process?”</p><p>Translational Cancer Research Award&#58;<br>2016 AACR-Conquer Cancer Foundation of ASCO Young Investigator Translational Cancer Research Award<br>•&#160;Julia Carnevale, MD, University of California, San Francisco<br>&#160;“New Treatments for Pancreatic Cancer with Homologous Recombination Defects”</p><p>Career Development Awards&#58;<br>2016 AACR-Aflac, Inc. Career Development Award for Pediatric Cancer Research <br>•&#160;Birgit Knoechel, MD, PhD, Dana-Farber Cancer Institute, Boston<br>&#160;“Mechanisms of Enhancer Rewiring in Drug Resistant T-ALL”</p><p>2015 AACR-Genentech BioOncology Career Development Award for Cancer Research on the HER Family Pathway<br>•&#160;Christine M. Lovly, MD, PhD, Vanderbilt University, Nashville, Tennessee<br>“Novel and Therapeutically Actionable EGFR Rearrangements in Lung Cancer”</p><p>2016 AACR-Incyte Corporation Career Development Award for Pancreatic Cancer Research<br>•&#160;Laura DeLong Wood, MD, PhD, Johns Hopkins University, Baltimore<br>“Investigation of Genetic Heterogeneity in Pancreatic Cancer Precursors”</p><p>2016 AACR-Triple Negative Breast Cancer Foundation-Carol’s Crusade for a Cure Foundation Career Development Award for Metastatic Triple Negative Breast Cancer Research<br>•&#160;Christina Curtis, PhD, MSc, Stanford University, Stanford, California<br>“Delineating the Dynamics of Triple Negative Breast Cancer Metastasis”</p><p>2016 Breast Cancer Research Foundation-AACR Career Development Awards for Translational Breast Cancer Research<br>•&#160;Brooke M. Emerling, PhD, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California<br>&#160;“Targeting PI5P4K for Triple Negative Breast Cancer Therapy”<br>•&#160;Wenqi Wang, PhD, The University of Texas MD Anderson Cancer Center, Houston<br>“Targeting the Hippo-YAP Pathway for Breast Cancer Treatment”</p><p>2016 Debbie’s Dream Foundation-AACR Career Development Award for Gastric Cancer Research<br>•&#160;Elise S. Demitrack, PhD, University of Michigan, Ann Arbor<br>“Mechanisms of Wnt Activation in FAP Gastric Polyps and Gastric Cancer”</p><p>Independent Investigator Awards&#58;<br>2015 Kure It-AACR Research Grant for Immunotherapy in Kidney Cancer<br>•&#160;Eliezer M. Van Allen, MD, Dana-Farber Cancer Institute, Boston<br>“Response Predictors to PD-1/PD-L1 Inhibitors in Renal Cell Carcinoma”</p><p>2016 Kure It-AACR Research Grant for Immunotherapy in Kidney Cancer<br>•&#160;Anna Meseguer, PhD, Vall D'Hebron University Hospital Research Institute, Barcelona<br>“Could TIM-1 Constitute a New Target for Renal Carcinoma Immunotherapy?”</p><p>2016 Neuroendocrine Tumor Research Foundation-AACR Grant<br>•&#160;Xianxin Hua, MD, PhD, University of Pennsylvania, Philadelphia<br>“Targeting Neuroendocrine Tumors by Suppressing a Cell-surface Protease”<br></p></div>
AACR Strongly Supports Yesterday’s Decision by the FDA to Regulate All Tobacco Products, From Electronic Cigarettes to Cigars and Hookahs165145/6/2016 1:38:45 PM Releases/AllItems.aspx890False2016-05-06T13:45:00ZSweeping new rule would give the FDA extended authority over previously unregulated tobacco products<div class="ExternalClass430A41F16D5B4BC795A3AD38F508B51E"><p>PHILADELPHIA — The American Association for Cancer Research (AACR) believes the FDA took a major step yesterday to promote and protect the nation's health by asserting its jurisdiction to regulate all tobacco products, including electronic (e-) cigarettes, cigars, pipe tobacco, and waterpipe tobacco. The regulation also authorizes the Secretary of Health and Human Services to request the FDA to conduct regulatory reviews of all tobacco products that went on sale after Feb. 15, 2007.</p><p>&quot;Tobacco is the leading cause of preventable death in the United States and it is associated with 18 different types of cancers,&quot; said Margaret Foti, PhD, MD (hc), chief executive officer of the AACR.&#160; &quot;Therefore, this action by the FDA is vitally important, especially if we are to protect our nation's youth from becoming addicted to nicotine. In fact, one of the most encouraging elements of this new rule is that it bans these tobacco products from being sold to anyone under 18, and the products will carry prominent warning labels.&quot;</p><p>While the FDA has exercised regulatory authority over some tobacco-based products such as cigarettes and smokeless tobacco, several others, including e-cigarettes and cigars, had remained unregulated until now. In the absence of such regulation, the emergence of e-cigarettes and other electronic nicotine delivery systems (ENDS) has become a major public health concern. While significant research is ongoing regarding their potential merits as smoking cessation tools, the possible popularity of e-cigarettes among the youth and young adult population continues to increase.</p><p>&quot;We simply do not know enough about the long-term consequences of e-cigarette use, nor do we know whether they are truly effective as a long-term smoking cessation aid,&quot; said Roy S. Herbst, MD, PhD, chair of the AACR Tobacco and Cancer Subcommittee and chief of medical oncology at Yale Comprehensive Cancer Center. &quot;Therefore, in addition to the FDA taking&#160;this critical step to regulate these products, it's going to be extremely important to support research on the health consequences of these products, as well as investigate the potential benefits of e-cigarettes as a cessation tool for those people already addicted to nicotine.&quot;</p><p>In addition to e-cigarettes, the smoking of cigars has increased significantly among youth and young adults since the use of flavorings was banned for traditional cigarettes. Today, a similar percentage of high school boys is smoking cigars (10.8 percent) compared to cigarettes (10.6 percent) according to a study by the Centers for Disease Control and Prevention (CDC). When those numbers are combined with the estimated 2.4 million occasional youth users of e-cigarettes, it is clear that the FDA's extended authority over both products will have a significant impact on the protection of users and those exposed to secondhand smoke or aerosol. With regard to cigars, the AACR commends the FDA for regulating all cigar ingredients, packaging, and labeling in the new deeming rule.</p><p>In January 2015, the AACR and the American Society of Clinical Oncology (ASCO) released a <a href="http&#58;//" target="_blank">joint policy statement</a> detailing recommendations for the regulation of e-cigarettes and other ENDS. The AACR is pleased to see that the FDA's deeming rule has adopted many of these recommendations by requiring a pre-market review process that will prevent misleading claims by tobacco product manufacturers and require the disclosure of ingredients contained within all tobacco products. This product review process would also give the FDA the authority to review product ingredients, design, and labeling with a specific emphasis on flavors and messaging that appeal to youth and non-users. The joint policy statement specifically recommended that the FDA require health warning and safety labels, including a warning regarding nicotine addiction, and&#160;the AACR is&#160;extremely pleased to see the full implementation of this recommendation within the deeming rule.</p></div>